FacebookTwitterGoogle+RedditEmail

Can Wyeth Fool American Women Twice?

Can Wyeth win back the 40 million Premarin and Prempro users it’s lost since 2002–along with $1 billion a year in profits–with a new menopause drug?

Or will the once-bitten women who have filed more than 5,000 law suits claiming the hormones gave them cancer feel fooled twice?

Pristiq, a serotonin/norepinephrine reuptake inhibitor (SNRI), is a metabolite of Wyeth’s antidepressant Effexor XR–which netted $3.7 billion in 2006–and an unabashed patent extender since Effexor XR goes off patent in 2010.

In February Pristiq was approved by the FDA for the treatment of adults with major depressive disorder but its launch as the first non-hormonal treatment for menopausal symptoms is what Wyeth hopes will fill the Premarin/Prempro/Effexor black hole to the tune of $2 billion a year.

Unfortunately, instead of a green light to market Pristiq for menopause last July, the FDA–also once bitten after Vioxx, Avandia and Vytroin–said to Wyeth not so fast.

Why did two women in the study group taking Pristiq have heart attacks and three need procedures to repair clogged arteries compared with none taking placebo it wanted to know? How can Wyeth assure long term safety when 604 of the 2,158 test subjects took Pristiq for only six months and 318 for a year or more? And what about serious liver complications seen in the studies?

Nor do drug industry insiders on the chatroom cafepharma sound like they’re scooping up Wyeth stock.

“Pristiq is not a good drug by any standard,” wrote one anonymous poster. “We tried to get 100 mg approved as the standard dose. But our patients got so sick that they could care less about the efficacy. They just couldn’t tolerate the drug long enough to see any improvement.”

Like longer than six months?

“No study exists showing any anti-depressant including Pristiq works any better than a placebo for reducing hot flashes, which are subjective anyway and only last a few minutes long at worst,” wrote another anonymous poster. “That is a heavy price to pay to take a heavy duty drug 24/7 for a few minutes of daily relief that a sugar pill also provides. FDA is crazy (or bought) if they allow this unproven drug travesty on the market.”

A third poster predicted women wouldn’t trade, “hot flashes for decreased libido, nausea, increased blood pressure and incredible withdrawal issues,” found with Pristiq. “Women and their physicians are not as gullible as they were back in the Premarin days.”

Even psychiatrist Daniel Carlat who wrote an expose for the New York Times magazine called Dr. Drug Rep last year about his experiences as a Wyeth paid spokesman, is dissing Pristiq.

“Every patient who takes Effexor produces Pristiq in their own body, at no additional charge,” he writes in a blog article called Top 5 Reasons to Forget About Pristiq.

Moreover Wyeth’s own investigator on the major Pristiq trials, Dr. Michael Liebowitz, admits it is “not a revolutionary drug” writes Carlat.

Of course you can’t blame a one trick company that cut its teeth on the Feminine Forever idea that age in women is a disease that needs treating for churning the demographics. Especially as it lays off 1,200 US workers, closes manufacturing plants and fights for its life.

Was it Wyeth’s fault that the hormone “therapy” it pushed for decades actually increases breast cancer by 26 percent, heart attacks by 29 percent, stroke by 41 percent and doubles the risk of blood clots and dementia?

But if US women embrace a major psychiatric drug with possible liver and heart complication side effects after the hormone hoax–manufactured by the same company and at four times the cost of Prempro/Premarin, $4 per day–

Fool me twice–?

MARTHA ROSENBERG is staff cartoonist on the Evanston Roundtable. She can be reached at mrosenberg@evmark.org

 

Your Ad Here
 

 

 

 

 

More articles by:

Martha Rosenberg is an investigative health reporter. She is the author of  Born With A Junk Food Deficiency: How Flaks, Quacks and Hacks Pimp The Public Health (Prometheus).

September 20, 2018
Michael Hudson
Wasting the Lehman Crisis: What Was Not Saved Was the Economy
John Pilger
Hold the Front Page, the Reporters are Missing
Kenn Orphan
The Power of the Anthropocene
Paul Cox – Stan Cox
Puerto Rico’s Unnatural Disaster Rolls on Into Year Two
Rajan Menon
Yemen’s Descent Into Hell: a Saudi-American War of Terror
Russell Mokhiber
Nick Brana Says Dems Will Again Deny Sanders Presidential Nomination
Nicholas Levis
Three Lessons of Occupy Wall Street, With a Fair Dose of Memory
Steve Martinot
The Constitutionality of Homeless Encampments
Kevin Zeese - Margaret Flowers
The Aftershocks of the Economic Collapse Are Still Being Felt
Jesse Jackson
By Enforcing Climate Change Denial, Trump Puts Us All in Peril
George Wuerthner
Coyote Killing is Counter Productive
Mel Gurtov
On Dealing with China
Dean Baker
How to Reduce Corruption in Medicine: Remove the Money
September 19, 2018
Bruce E. Levine
When Bernie Sold Out His Hero, Anti-Authoritarians Paid
Lawrence Davidson
Political Fragmentation on the Homefront
George Ochenski
How’s That “Chinese Hoax” Treating You, Mr. President?
Cesar Chelala
The Afghan Morass
Chris Wright
Three Cheers for the Decline of the Middle Class
Howard Lisnoff
The Beat Goes On Against Protest in Saudi Arabia
Nomi Prins 
The Donald in Wonderland: Down the Financial Rabbit Hole With Trump
Jack Rasmus
On the 10th Anniversary of Lehman Brothers 2008: Can ‘IT’ Happen Again?
Richard Schuberth
Make Them Suffer Too
Geoff Beckman
Kavanaugh in Extremis
Jonathan Engel
Rather Than Mining in Irreplaceable Wilderness, Why Can’t We Mine Landfills?
Binoy Kampmark
Needled Strawberries: Food Terrorism Down Under
Michael McCaffrey
A Curious Case of Mysterious Attacks, Microwave Weapons and Media Manipulation
Elliot Sperber
Eating the Constitution
September 18, 2018
Conn Hallinan
Britain: the Anti-Semitism Debate
Tamara Pearson
Why Mexico’s Next President is No Friend of Migrants
Richard Moser
Both the Commune and Revolution
Nick Pemberton
Serena 15, Tennis Love
Binoy Kampmark
Inconvenient Realities: Climate Change and the South Pacific
Martin Billheimer
La Grand’Route: Waiting for the Bus
John Kendall Hawkins
Seymour Hersh: a Life of Adversarial Democracy at Work
Faisal Khan
Is Israel a Democracy?
John Feffer
The GOP Wants Trumpism…Without Trump
Kim Ives
The Roots of Haiti’s Movement for PetroCaribe Transparency
Dave Lindorff
We Already Have a Fake Billionaire President; Why Would We want a Real One Running in 2020?
Gerry Brown
Is China Springing Debt Traps or Throwing a Lifeline to Countries in Distress?
Pete Tucker
The Washington Post Really Wants to Stop Ben Jealous
Dean Baker
Getting It Wrong Again: Consumer Spending and the Great Recession
September 17, 2018
Melvin Goodman
What is to be Done?
Rob Urie
American Fascism
Patrick Cockburn
The Adults in the White House Trying to Save the US From Trump Are Just as Dangerous as He Is
Jeffrey St. Clair - Alexander Cockburn
The Long Fall of Bob Woodward: From Nixon’s Nemesis to Cheney’s Savior
FacebookTwitterGoogle+RedditEmail